# Yun Zhang

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/yun-zhang/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8 |
| Field | Monoclonal and Polyclonal Antibodies Research |
| h-index | 2 |
| i10-index | 0 |
| Last Known Institution | Pfizer (United States) |
| OpenAlex ID | https://openalex.org/A5110903238 |
| ORCID iD | 0009-0008-7526-8892 |
| Works | 24 |

## Researcher papers

- [Analysis of the effect of comprehensive physical and mental nursing for patients with acute cerebral infarction in intravenous thrombolytic therapy](https://scholariq.org/papers/analysis-of-the-effect-of-comprehensive-physical-and-mental-nursing-for-patients/)
- [A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies](https://scholariq.org/papers/a-novel-b7-h4xcd3-bispecific-t-cell-engager-pf-07260437-synergizes-with-breast/)
- [Data from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies](https://scholariq.org/papers/data-from-a-novel-b7-h4xcd3-bispecific-t-cell-engager-pf-07260437-synergizes/)
- [Supplementary Table S13 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies](https://scholariq.org/papers/supplementary-table-s13-from-a-novel-b7-h4xcd3-bispecific-t-cell-engager-pf/)
- [Supplementary Figure S1 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies](https://scholariq.org/papers/supplementary-figure-s1-from-a-novel-b7-h4xcd3-bispecific-t-cell-engager-pf/)
- [Supplementary Figure S5 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies](https://scholariq.org/papers/supplementary-figure-s5-from-a-novel-b7-h4xcd3-bispecific-t-cell-engager-pf/)
- [Supplementary Table S1 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies](https://scholariq.org/papers/supplementary-table-s1-from-a-novel-b7-h4xcd3-bispecific-t-cell-engager-pf/)
- [Supplementary Table S12 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies](https://scholariq.org/papers/supplementary-table-s12-from-a-novel-b7-h4xcd3-bispecific-t-cell-engager-pf/)
- [Supplementary Table S9 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies](https://scholariq.org/papers/supplementary-table-s9-from-a-novel-b7-h4xcd3-bispecific-t-cell-engager-pf/)
- [Supplementary Figure S6 from A Novel B7-H4xCD3 Bispecific T-cell Engager (PF-07260437) Synergizes with Breast Cancer Standard of Care and Immune Checkpoint Therapies](https://scholariq.org/papers/supplementary-figure-s6-from-a-novel-b7-h4xcd3-bispecific-t-cell-engager-pf/)

## Researcher topics

- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Acute Ischemic Stroke Management](https://scholariq.org/topics/acute-ischemic-stroke-management/)

## Researcher university

- [Pfizer (United States)](https://scholariq.org/institutions/pfizer-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.